ACTAVIS has announced a
settlement agreement with Shire
Pharmaceuticals, resolving patent
litigation over Actavis’ generic
version of Intuniv (guanfacine
hydrochloride) for the treatment
of Attention Deficit Hyperactivity
Disorder.
The FDA approved Actavis’ version
last Oct, and under the terms of the
deal Actavis can launch a generic
version of Intuniv on 01 Dec 2014.
Shire will receive a 25% royalty on
Actavis’ gross profits from the first
six months of sales.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Apr 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.